NCT04734080View on ClinicalTrials.gov

Dronabinol in Total Knee Arthroplasty (TKA)

PHASE4CompletedINTERVENTIONAL

Enrollment

114

Participants

Timeline

Start Date

March 1, 2021

Primary Completion Date

October 6, 2023

Study Completion Date

April 1, 2024

Conditions

Total Knee ArthroplastyOpioid Use

Interventions

DRUG

Dronabinol 5mg Cap

Dronabinol is a synthetic tetrahydrocannabinol (THC) agent approved for nausea and vomiting with chemotherapy and as an appetite stimulant in AIDS patients.

OTHER

Placebo oral tablet

Non-active placebo

Trial Locations (1)

10021

Hospital for Special Surgery, New York

All Listed Sponsors

lead

Hospital for Special Surgery, New York

OTHER

NCT04734080 - Dronabinol in Total Knee Arthroplasty (TKA) | Biotech Hunter | Biotech Hunter